Benefit assessment in Germany: implications for price discounts

Health Economics Review

Table 7 Results of the univariate regression^a (N = 193)

Predictor (X)	n	Beta	SE	Coeff (β)	p-value	R²
Additional benefit	100	−0.041	0.019	−0.156	0.030*	0.024
Major	1	−0.084	0.132	−0.046	0.527	0.002
Considerable	29	−0.015	0.027	−0.042	0.564	0.002
Minor	48	−0.014	0.022	−0.045	0.532	0.002
Non-quantifiable	22	−0.052	0.030	−0.127	0.078	0.016
No additional benefit	92	0.044	0.019	0.167	0.020*	0.028
Less benefit (additional harm potential)	1	−0.130	0.132	−0.071	0.324	0.005
Orphan status	29	−0.043	0.026	−0.117	0.104	0.014
Indication per category
Certain infectious and parasitic diseases	51	0.001	0.022	0.002	0.975	0.000
Diseases of the blood and blood-forming organs	2	0.026	0.094	0.020	0.784	0.000
Diseases of the circulatory system	14	0.035	0.036	0.070	0.332	0.005
Diseases of the digestive system	6	0.056	0.054	0.075	0.303	0.006
Diseases of the eye and adnexa	7	−0.026	0.051	−0.037	0.609	0.001
Diseases of the genitourinary system	2	−0.022	0.094	−0.017	0.816	0.000
Diseases of the musculoskeletal system and connective tissue	1	0.176	0.131	0.096	0.183	0.008
Diseases of the nervous system	9	0.167	0.043	0.268	0.000**	0.072
Diseases of the respiratory system	9	−0.095	0.044	−0.152	0.034*	0.023
Diseases of the skin and subcutaneous tissue	1	0.209	0.131	0.114	0.113	0.013
Endocrine, nutritional and metabolic diseases	24	−0.024	0.029	−0.060	0.403	0.004
Mental and behavioral disorders	2	0.038	0.094	0.029	0.689	0.001
Neoplasms	57	−0.028	0.021	−0.097	0.181	0.009
Other	8	−0.013	0.048	−0.020	0.787	0.000
Number of ACT >1	83	0.016	0.019	0.059	0.418	0.003
Incorporated HRQoL-data	49	−0.036	0.022	−0.119	0.100	0.014

Abbreviations: HRQoL health-related quality of life, Beta standardized coefficient, SE standard error, Coeff coefficient, R ² coefficient of determination
** Significant at the 0.01 level
* Significant at the 0.05 level
^a Dependent Variable (Y): price change (discount)

ISSN: 2191-1991